Compare ALIT & TLRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALIT | TLRY |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Business Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | N/A | 2018 |
| Metric | ALIT | TLRY |
|---|---|---|
| Price | $1.90 | $9.26 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | $5.25 | ★ $150.00 |
| AVG Volume (30 Days) | 13.7M | ★ 19.7M |
| Earning Date | 02-19-2026 | 01-08-2026 |
| Dividend Yield | ★ 8.79% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,289,000,000.00 | $830,766,000.00 |
| Revenue This Year | N/A | $7.28 |
| Revenue Next Year | $1.56 | $4.51 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2.31 |
| 52 Week Low | $1.82 | $3.51 |
| 52 Week High | $7.66 | $23.20 |
| Indicator | ALIT | TLRY |
|---|---|---|
| Relative Strength Index (RSI) | 34.62 | 55.72 |
| Support Level | $1.90 | $8.84 |
| Resistance Level | $2.00 | $9.85 |
| Average True Range (ATR) | 0.09 | 1.27 |
| MACD | 0.00 | -0.48 |
| Stochastic Oscillator | 20.03 | 6.26 |
Alight Inc is a technology-enabled services company delivering human capital management solutions to many of complex organizations. This includes the implementation and administration of employee benefits (e.g., health, wealth and leaves benefits) solutions, currently operates under one reportable segment, Employer Solutions. The Company completed the Divestiture of Alight's Professional Services segment and Alight's Payroll & HCM Outsourcing business within the Employer Solutions segment. The company operates in USA states and International market too.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.